Hyunseok Kang, MD

Professor of Clinical Medicine

Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. Dr.Kang joined UCSF from the Johns Hopkins University School of Medicine in Baltimore, MD where he was an Assistant Professor of Oncology, Otolaryngology - Head and Neck Surgery.

Dr.Kang completed his medical degree and public health degree at Yonsei University in Seoul, South Korea, then came to the US and had residency training at St.Luke's Roosevelt Hospital Center/Columbia University in New York City. He completed hematology and medical oncology fellowship at Emory University in Atlanta, GA.

Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents.

Education
06/2021 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 06/2013 - Hematology&Oncology, Emory University
Residency, 06/2010 - Internal Medicine, St.Luke's-Roosevelt Hospital/Columbia University
M.P.H., 08/2007 - Epidemiology & Statistics, Yonsei University
M.D., 02/2002 - Medicine, Yonsei University
Honors and Awards
  • Elected to a fellow (FACP), American College of Physicians, 2015
  • Travel Award for Methods in Clinical Research Workshop, AACR/ASCO, 2012
  • Excellence in Service Award, Ministry of Health and Welfare of Korea, 2005
Publications

  1. Cui Z, Kang H, Li H, Lee ED, Lee YS, Peterson CN, Long SR, Grandis JR, Johnson DE. CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer. Head & neck 2024. PMID: 39347568


  2. Chin A, Lindsay S, Bergsland EK, Kang H. Withdrawal pain following patients discontinuing Trk inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2024. PMID: 39191376


  3. Buckley MW, Balaji Warner A, Brahmer J, Cappelli LC, Sharfman WH, Fuchs E, Kang H, Forde PM, Gladstone DE, Ambinder R, Kelly RJ, Lipson EJ, Gojo I, Lee EJ, Johnson TP, Saidha S, Llinas R, Ostrow LW, Naidoo J, Probasco JC. Immune-related encephalitis after immune checkpoint inhibitor therapy. The oncologist 2024. PMID: 39066587


  4. Diwanji D, Carrodeguas E, Seo Y, Kang H, Soe MH, Chiang JM, Zhang L, Liu C, Behr SC, Flavell RR. Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers. Journal of clinical medicine 2024. PMID: 38999527


  5. Raez LE, Kang H, Ohe Y, Khanal M, Han Y, Szymczak S, Barker SS, Gilligan AM. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. ESMO open 2024. PMID: 38749381


  6. Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral oncology 2023. PMID: 38118249


  7. Humphries A, Zhou CJ, Welsh M, Lem M, Kang H, Algazi AP. Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Head & neck 2023. PMID: 37997549


  8. Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2023. PMID: 37643133


  9. Lee RH, Truong A, Wu X, Kang H, Algazi AP, El-Sayed IH, George JR, Heaton CM, Ryan WR, Ha PK, Wai KC. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab. Head & neck 2023. PMID: 37897202


  10. Plonowska-Hirschfeld KA, Gulati A, Stephens EM, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi A, Kang H, Ryan WR. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma. The Laryngoscope 2023. PMID: 37767815


  11. Gulati A, Plonowska-Hirschfeld K, Stephens EM, Kansara S, Zebolsky AL, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR. A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2023. PMID: 37212448


  12. Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute 2022. PMID: 36053203


  13. Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer medicine 2022. PMID: 36479637


  14. Lee RH, Wai KC, Chan JW, Ha PK, Kang H. Approaches to the Management of Metastatic Adenoid Cystic Carcinoma. Cancers 2022. PMID: 36428790


  15. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. The Lancet. Oncology 2022. PMID: 36108661


  16. Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 35867947


  17. Soe MH, Chiang JM, Flavell RR, Khanafshar E, Mendoza L, Kang H, Liu C. Non-iodine Avid Disease is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer with Papillary Histology. 2022. PMID: 35556126


  18. Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. 2022. PMID: 35217573


  19. Park JC, Ashok A, Liu C, Kang H. Real-World Experience of NTRK Fusion-Positive Thyroid Cancer. 2022. PMID: 35171659


  20. Min S, Kang H. What’s New in Molecular Targeted Therapies for Thyroid Cancer? Korean J Head Neck Oncol 2022. PMID:


  21. Jin N, Keam B, Cho J, Lee MJ, Kim HR, Torosyan H, Jura N, Ng PK, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Bauman JE, Kim MO, VanLandingham NK, Swaney DL, Krogan NJ, Johnson DE, Grandis JR. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. The Journal of clinical investigation 2021. PMID: 34779417


  22. Kim K, Kim CW, Shin A, Kang H, Jung SJ. Effect of chemotherapy and radiotherapy on cognitive impairment in colorectal cancer: evidence from national representative longitudinal database. 2021. PMID: 34735757


  23. Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research 2021. PMID: 34045293


  24. Vellanki PJ, DeBoy EA, Bawadkji MM, Schuchter L, Rooper L, Mehra R, Kang H, Armanios M. Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations. 2021. PMID: 34568721


  25. Wai KC, Kang H, Ha PK. Molecular Markers that Matter in Salivary Malignancy. 2021. PMID: 34024488


  26. Humtsoe JO, Kim HS, Leonard B, Ling S, Keam B, Marchionni L, Afsari B, Considine M, Favorov AV, Fertig EJ, Kang H, Ha PK. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer research 2021. PMID: 33408119


  27. Cui Z, Kang H, Grandis JR, Johnson DE. CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers. Molecular cancer research : MCR 2020. PMID: 32883697


  28. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. The New England journal of medicine 2020. PMID: 32846061


  29. Park JC, Durbeck J, Boudadi K, Ho WJ, Kang H. The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. Oral oncology 2020. PMID: 32792211


  30. Jung K, Narwal M, Min SY, Keam B, Kang H. Squamous cell carcinoma of head and neck: what internists should know. The Korean journal of internal medicine 2020. PMID: 32663913


  31. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of oncology : official journal of the European Society for Medical Oncology 2019. PMID: 32067683


  32. Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head & neck 2018. PMID: 30478962


  33. Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head & neck 2018. PMID: 30421818


  34. Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. The oncologist 2018. PMID: 30373905


  35. Kwatra SG, Ständer S, Kang H. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. The New England journal of medicine 2018. PMID: 30332571


  36. Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. The oncologist 2018. PMID: 30297384


  37. Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. Journal for immunotherapy of cancer 2018. PMID: 30170629


  38. Jung K, Park JC, Kang H, Brandes J. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the US veterans with prostate cancer. Epidemiology and health 2018. PMID: 30121970


  39. Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. Volume 42 of Issue 8. The American journal of surgical pathology 2018. PMID: 29683815


  40. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Volume 119 of Issue 2. British journal of cancer 2018. PMID: 29955135


  41. Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Volume 84. Oral oncology 2018. PMID: 30122219


  42. Ho WJ, Rooper L, Sagorsky S, Kang H. A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. Volume 6 of Issue 1. Journal for immunotherapy of cancer 2018. PMID: 29743117


  43. Motz K, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Eisele DW, Koch WM, Frick KD, Gourin CG. Short- and long-term outcomes of oropharyngeal cancer care in the elderly. The Laryngoscope 2018. PMID: 29573418


  44. Gourin CG, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Koch WM, Eisele DW, Frick KD. Quality indicators of oropharyngeal cancer care in the elderly. The Laryngoscope 2017. PMID: 29243261


  45. Gourin CG, Fakhry C, Quon H, Kang H, Kiess AP, Herbert RJ, Eisele DW, Frick KD. Treatment, survival, and costs of oropharyngeal cancer care in the elderly. The Laryngoscope 2017. PMID: 28988469


  46. Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Volume 74. Oral oncology 2017. PMID: 29103750


  47. Guerrero-Preston R, White JR, Godoy-Vitorino F, Rodríguez-Hilario A, Navarro K, González H, Michailidi C, Jedlicka A, Canapp S, Bondy J, Dziedzic A, Mora-Lagos B, Rivera-Alvarez G, Ili-Gangas C, Brebi-Mieville P, Westra W, Koch W, Kang H, Marchionni L, Kim Y, Sidransky D. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and Volume 8 of Issue 67. Oncotarget 2017. PMID: 29340028


  48. Fung N, Faraji F, Kang H, Fakhry C. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. Cancer metastasis reviews 2017. PMID: 28812214


  49. Britt CJ, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Quality indicators of laryngeal cancer care in commercially insured patients. The Laryngoscope 2017. PMID: 28688188


  50. Day AT, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. The Laryngoscope 2017. PMID: 28685830


  51. Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO precision oncology 2017. PMID: 30003184


  52. Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Volume 23 of Issue 17. Clinical cancer research : an official journal of the American Association for Cancer Research 2017. PMID: 28522603


  53. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Volume 35 of Issue 14. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017. PMID: 28328302


  54. D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C. Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. JAMA oncology 2016. PMID: 27930766


  55. Malm IJ, Fan CJ, Yin LX, Li DX, Koch WM, Gourin CG, Pitman KT, Richmon JD, Westra WH, Kang H, Quon H, Eisele DW, Fakhry C. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Volume 123 of Issue 10. Cancer 2017. PMID: 28055120


  56. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Volume 7 of Issue 3. Cancer discovery 2016. PMID: 28031159


  57. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Volume 34 of Issue 32. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016. PMID: 27646946


  58. Kang H, Tan M, Bishop JA, Jones S, Sausen M, Ha PK, Agrawal N. Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Volume 23 of Issue 1. Clinical cancer research : an official journal of the American Association for Cancer Research 2016. PMID: 27340278


  59. Taghipour M, Sheikhbahaei S, Wray R, Agrawal N, Richmon J, Kang H, Subramaniam RM. FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. Volume 206 of Issue 5. AJR. American journal of roentgenology 2016. PMID: 26999264


  60. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Volume 53. Oral oncology 2015. PMID: 26705063


  61. Sheikhbahaei S, Ahn SJ, Moriarty E, Kang H, Fakhry C, Subramaniam RM. Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. AJR. American journal of roentgenology 2015. PMID: 26496559


  62. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Volume 7 of Issue 293. Science translational medicine 2015. PMID: 26109104


  63. Pasha MA, Marcus C, Fakhry C, Kang H, Kiess AP, Subramaniam RM. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. AJR. American journal of roentgenology 2015. PMID: 26001119


  64. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Volume 26 of Issue 6. Annals of oncology : official journal of the European Society for Medical Oncology 2015. PMID: 25712460


  65. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Volume 12 of Issue 1. Nature reviews. Clinical oncology 2014. PMID: 25403939


  66. Mohandas A, Marcus C, Kang H, Truong MT, Subramaniam RM. FDG PET/CT in the management of nasopharyngeal carcinoma. AJR. American journal of roentgenology 2014. PMID: 25055290


  67. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology 2014. PMID: 25081901


  68. Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014. PMID: 24947059


  69. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR, Brandes JC. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Volume 120 of Issue 9. Cancer 2014. PMID: 24664792


  70. Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer prevention research (Philadelphia, Pa.) 2014. PMID: 24441677


  71. Alviar CL, Devarapally S, Nadkarni GN, Romero J, Benjo AM, Javed F, Doherty B, Kang H, Bangalore S, Messerli FH. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. American journal of hypertension 2012. PMID: 23382415


  72. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology 2011. PMID: 21447628


  73. Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Current treatment options in oncology 2011. PMID: 21274667


  74. Kang H, Rha SY, Oh KW, Nam CM. Green tea consumption and stomach cancer risk: a meta-analysis. Epidemiology and health 2010. PMID: 21191454


  75. Kim H, Kim EK, Choi ES, Kim YJ, Lee HJ, Kim JJ, Jang HS, Shim KS, Jeon SN, Kang YH, Kang H, Oh J, Cho KS, Kwon S. [The determinants of adolescent smoking by gender and type of school in Korea]. Journal of preventive medicine and public health = Yebang Uihakhoe chi 2006. PMID: 17076178


  76. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clinical cancer research : an official journal of the American Association for Cancer Research 2000. PMID: 10656450